Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax

Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e556-e559. doi: 10.1016/j.clml.2020.05.028. Epub 2020 Jun 14.

Authors

Arshia Soleimani¹, Madhurima Koka², Zeba N Singh², Vivek Kesari³, Ashraf Badros⁴

Affiliations

¹ Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD.
² Department of Pathology, University of Maryland School of Medicine, Baltimore, MD.
³ Department of Radiology, University of Maryland School of Medicine, Baltimore, MD.
⁴ Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD. Electronic address: [email protected].

PMID: 32653454
DOI: 10.1016/j.clml.2020.05.028

No abstract available

Keywords: Biomarker driven therapy; Multiple myeloma; Relapsed and refractory; Translocation (11:4); Venetoclax.

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Humans
Male
Multiple Myeloma / complications*
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Sulfonamides / pharmacology
Sulfonamides / therapeutic use*

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax